106 related articles for article (PubMed ID: 11700273)
21. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B infection and aflatoxin biomarker levels in Gambian children.
Turner PC; Mendy M; Whittle H; Fortuin M; Hall AJ; Wild CP
Trop Med Int Health; 2000 Dec; 5(12):837-41. PubMed ID: 11169271
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B vaccination in children: the Taiwan experience.
Ni YH; Chen DS
Pathol Biol (Paris); 2010 Aug; 58(4):296-300. PubMed ID: 20116181
[TBL] [Abstract][Full Text] [Related]
24. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads.
Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Hsu CA; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
Hepatology; 2013 Feb; 57(2):441-50. PubMed ID: 22941922
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical detection of aflatoxin B1-DNA adducts and hepatitis B virus antigens in hepatocellular carcinoma and nontumorous liver tissue.
Santella RM; Zhang YJ; Chen CJ; Hsieh LL; Lee CS; Haghighi B; Yang GY; Wang LW; Feitelson M
Environ Health Perspect; 1993 Mar; 99():199-202. PubMed ID: 8391434
[TBL] [Abstract][Full Text] [Related]
26. Interactions between hepatitis B virus and aflatoxin B(1): effects on p53 induction in HepaRG cells.
Lereau M; Gouas D; Villar S; Besaratinia A; Hautefeuille A; Berthillon P; Martel-Planche G; Nogueira da Costa A; Ortiz-Cuaran S; Hantz O; Pfeifer GP; Hainaut P; Chemin I
J Gen Virol; 2012 Mar; 93(Pt 3):640-650. PubMed ID: 22113009
[TBL] [Abstract][Full Text] [Related]
27. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.
Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Wang LY; You SL; Iloeje UH; Chen CJ;
Gastroenterology; 2010 Aug; 139(2):474-82. PubMed ID: 20434450
[TBL] [Abstract][Full Text] [Related]
28. Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan.
Shirabe K; Toshima T; Taketomi A; Taguchi K; Yoshizumi T; Uchiyama H; Harimoto N; Kajiyama K; Egashira A; Maehara Y
Liver Int; 2011 Oct; 31(9):1366-72. PubMed ID: 21745313
[TBL] [Abstract][Full Text] [Related]
29. Molecular dosimetry of aflatoxin-N7-guanine in human urine obtained in The Gambia, West Africa.
Groopman JD; Hall AJ; Whittle H; Hudson GJ; Wogan GN; Montesano R; Wild CP
Cancer Epidemiol Biomarkers Prev; 1992; 1(3):221-7. PubMed ID: 1339082
[TBL] [Abstract][Full Text] [Related]
30. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study.
Fwu CW; Chien YC; Kirk GD; Nelson KE; You SL; Kuo HS; Feinleib M; Chen CJ
J Natl Cancer Inst; 2009 Jul; 101(14):1019-27. PubMed ID: 19535774
[TBL] [Abstract][Full Text] [Related]
32. Aflatoxin B1-DNA adducts and hepatitis B virus antigens in hepatocellular carcinoma and non-tumorous liver tissue.
Zhang YJ; Chen CJ; Lee CS; Haghighi B; Yang GY; Wang LW; Feitelson M; Santella R
Carcinogenesis; 1991 Dec; 12(12):2247-52. PubMed ID: 1721008
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B e antigen and the risk of hepatocellular carcinoma.
Yang HI; Lu SN; Liaw YF; You SL; Sun CA; Wang LY; Hsiao CK; Chen PJ; Chen DS; Chen CJ;
N Engl J Med; 2002 Jul; 347(3):168-74. PubMed ID: 12124405
[TBL] [Abstract][Full Text] [Related]
34. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.
Tseng TC; Liu CJ; Su TH; Wang CC; Chen CL; Chen PJ; Chen DS; Kao JH
Gastroenterology; 2011 Aug; 141(2):517-25, 525.e1-2. PubMed ID: 21672542
[TBL] [Abstract][Full Text] [Related]
35. Changing serum levels of quantitative hepatitis B surface antigen and hepatitis B virus DNA in hepatitis B virus surface antigen carriers: a follow-up study of an elderly cohort.
Kuo YH; Chang KC; Wang JH; Tsai PS; Hung SF; Hung CH; Lu SN
Kaohsiung J Med Sci; 2015 Feb; 31(2):102-7. PubMed ID: 25645989
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study.
Ruan P; Xu SY; Zhou BP; Huang J; Gong ZJ
J Int Med Res; 2013 Oct; 41(5):1732-9. PubMed ID: 23908397
[TBL] [Abstract][Full Text] [Related]
37. The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma.
Smela ME; Hamm ML; Henderson PT; Harris CM; Harris TM; Essigmann JM
Proc Natl Acad Sci U S A; 2002 May; 99(10):6655-60. PubMed ID: 12011430
[TBL] [Abstract][Full Text] [Related]
38. Determinants of formation of aflatoxin-albumin adducts: a seven-township study in Taiwan.
Sun CA; Wu DM; Wang LY; Chen CJ; You SL; Santella RM
Br J Cancer; 2002 Oct; 87(9):966-70. PubMed ID: 12434285
[TBL] [Abstract][Full Text] [Related]
39. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load.
Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
Gastroenterology; 2012 May; 142(5):1140-1149.e3; quiz e13-4. PubMed ID: 22333950
[TBL] [Abstract][Full Text] [Related]
40. Toll-like receptor and hepatitis B virus clearance in chronic infected patients: a long-term prospective cohort study in Taiwan.
Wu JF; Chen CH; Ni YH; Lin YT; Chen HL; Hsu HY; Chang MH
J Infect Dis; 2012 Sep; 206(5):662-8. PubMed ID: 22740716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
